CorMedix Inc. (NASDAQ:CRMD) disclosed that its Chief Executive Officer and Director, Joseph Todisco, acquired 80,000 shares of the company's common stock on November 13, 2026. The total value of the transaction amounted to $391,200.
The shares were purchased at a weighted average price of $4.89. The transactions were executed in multiple trades with prices ranging from $4.85 to $5.00 per share. The timing of this insider purchase is notable, as the stock is currently trading at $4.66, near its 52-week low of $4.65, after declining nearly 15% over the past week. According to InvestingPro analysis, CRMD appears undervalued at current levels, with the stock trading at a P/E ratio of just 6.62. Investors can access the full Fair Value analysis and 13 additional ProTips on InvestingPro.
Following this acquisition, Mr. Todisco directly beneficially owns 854,749 shares of CorMedix common stock.
In other recent news, CorMedix reported third-quarter revenue that surpassed Wall Street expectations, reaching $54.5 million. This marks a decrease from $104.3 million a year earlier. Despite the revenue beat, the company experienced a wider-than-expected net loss of $0.19 per share, against analysts' estimates of a $0.10 loss. The loss was attributed to adjustments in the reimbursement setting for its flagship product, DefenCath. Following these results, Oppenheimer adjusted its price target for CorMedix shares to $13 from $15, maintaining an Outperform rating. The firm revised its valuation model by removing TPN and incorporating Heron, which adds commercial revenue and leverages existing infrastructure. These developments reflect CorMedix's ongoing adjustments and strategic shifts in the market.
The insider purchase comes at a time when CorMedix shares are under pressure, trading near their 52-week low. The stock's decline of nearly 15% over the past week has raised questions about the company's near-term prospects. However, the CEO's decision to increase his stake could be interpreted as a signal of confidence in the company's long-term strategy, particularly following the recent reimbursement adjustments for DefenCath.
CorMedix's third-quarter results highlighted the impact of reimbursement changes on its financial performance. While revenue exceeded expectations, the wider net loss underscores the challenges the company faces in navigating the evolving reimbursement landscape. Oppenheimer's revised price target and maintained Outperform rating suggest that the firm sees potential in CorMedix's strategic shifts, including the incorporation of Heron and the removal of TPN from its valuation model.
Investors will continue to monitor insider activity and analyst revisions for further clues about CorMedix's direction. The company's ability to manage reimbursement pressures and execute on its strategic initiatives will be key factors in determining its future performance.